Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016261 | 1.00 | LTA4H (0.57) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL2019556 | 1.00 | LTA4H (0.57) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL16439718 | 0.92 | LTA4H (0.55) | LTA4HSIGMAR1ALDH1A1LMNAGBA1 | |
| SCHEMBL19878947 | 0.92 | ALDH1A1 (0.51) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL14033540 | 0.92 | LTA4H (0.55) | LTA4HSIGMAR1ALDH1A1LMNAGBA1 | |
| SCHEMBL19878948 | 0.92 | ALDH1A1 (0.51) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL2062715 | 0.88 | LTA4H (0.60) | LTA4HSIGMAR1ALDH1A1GBA1FUCA1 | |
| SCHEMBL28142979 | 0.88 | LTA4H (0.60) | LTA4HSIGMAR1ALDH1A1GBA1FUCA1 | |
| SCHEMBL692066 | 0.88 | LTA4H (0.60) | LTA4HSIGMAR1ALDH1A1GBA1FUCA1 | |
| SCHEMBL3495379 | 0.87 | LTA4H (0.59) | LTA4HSIGMAR1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-117820333-A | KRAS G12C inhibitors | 伊莱利利公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024067818-A1 | CHIMERIC COMPOUND USED FOR TARGETED DEGRADATION OF BCL-2 PROTEIN, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2024-04-04 | — | — | WO | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-114828964-B | KRAS G12C inhibitors | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| CN-116724044-A | Tri-heterocyclic compound, preparation method and application thereof | 上海湃隆生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION | 2005-03-24 | — | — | US | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040242575-A1 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1434583-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-07 | — | — | EP | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003032991-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242575-A1 | N-aroyl piperazine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, CNR1 | LTA4H 1884/4885SIGMAR1 54/4885ALDH1A1 883/4885 |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | LTA4H 3006/4885SIGMAR1 2828/4885ALDH1A1 1144/4885 |
| US-11731984-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | LTA4H 4116/4885SIGMAR1 4512/4885ALDH1A1 2427/4885 |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | MCHR1, MCHR2, MC1R | LTA4H 2242/4885SIGMAR1 145/4885ALDH1A1 1263/4885 |
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | LTA4H 1769/4885SIGMAR1 4743/4885ALDH1A1 1500/4885 |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | LTA4H 3505/4885SIGMAR1 61/4885ALDH1A1 2465/4885 |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | LTA4H 2242/4885SIGMAR1 145/4885ALDH1A1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.